Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Repros reports no tumors in completed Proellex animal carcinogenicity study

Aug. 22, 2008

New treatment options for osteoporosis disclosed in recent Novartis patent

Aug. 22, 2008

New therapeutic agents for obesity described in recent patents

Aug. 22, 2008

Enobia begins testing of enzyme replacement therapy for hypophosphatasia

Aug. 21, 2008

Activx reports topline results from phase Ib and phase IIa clinical trials of KRP-1

Aug. 21, 2008

Noven enters license agreement with Procter & Gamble for HSDD patches

Aug. 21, 2008

Recent patent literature divulges novel treatment options for diabetes

Aug. 21, 2008

Novel CB1 receptor antagonist profiled at Bristol-Myers Squibb

Aug. 21, 2008

Transplantation of islet cells with Sertoli cells may be feasible for diabetes treatment

Aug. 20, 2008

Repros presents an update on phase II endometriosis study of Proellex

Aug. 20, 2008

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 18, 2026.
ASGCT 2026: Directed evolution in gene therapy
BioWorld
Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal
BioWorld
Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage...
Biogen AD drug shows tau, cognition benefit, despite trial miss
BioWorld
Biogen Inc. has decided to advance diranersen (BIIB-080) into registrational trials for early Alzheimer’s disease, even though the antisense oligonucleotide...